Cognitive deficits are a core clinical feature of schizophrenia but respond poorly to available
medications. Thus, understanding the neural basis of these deficits is crucial for the …

Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter that is required for
the control of synaptic excitation/inhibition and neural oscillation. GABA is synthesized by …

Mutations that cause intellectual disability (ID) and autism spectrum disorder (ASD) are
commonly found in genes that encode for synaptic proteins. However, it remains unclear …

Major depression disorder (MDD) is one of the most common psychiatric disorders and one
of the leading causes of disability in worldwide. Both inflammation and GABAergic …

Individuals with schizophrenia (SZ) exhibit cognitive performance below expected levels
based on familial cognitive aptitude. One such cognitive process, working memory (WM), is …

Inflammation has been implicated in the progression of neurological disease, yet precisely
how inflammation affects neuronal function remains unclear. Tumor necrosis factor-α (TNFα) …

Highlights•Parvalbumin (PV) cell alterations contribute to cognitive deficits in
schizophrenia.•PV cells have multiple gene expression disturbances that impair their …

Quantification of a number of neurochemicals within localised regions of tissue has long
been possible using Magnetic Resonance Spectroscopy (MRS). In recent years, MRS has …

Amyloid-β (Aβ) plaque accumulation in Alzheimer's disease (AD) is associated with
glutamatergic synapse loss, but less is known about its effect on inhibitory synapses. Here …

This article describes commonly used experimental and clinical biomarkers of neuronal
injury and neurodegeneration for the evaluation of neuropathology and monitoring of …